A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

The following is a summary of “Association of Perioperative Glucagon-like Peptide-1 Receptor Agonist Use and Postoperative ...

Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...

The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.

The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Topline data were announced from a phase 3 trial evaluating CagriSema in overweight or obese patients without type 2 diabetes ...

The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the ...

These drugs, called glucagon-like peptide-1 receptor agonists (GLP-1 RAs), work in several different ways to help people lose ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.